- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05098769
A Predictive Tool for Predicting Adverse Outcomes in Acute Pulmonary Embolism Patients Using CTPA.
A Predictive Tool for Predicting Adverse Outcomes in Acute Pulmonary Embolism Patients Using Parameters Obtained by Computed Tomographic Pulmonary Angiography.
Study Overview
Status
Detailed Description
This study collected clinical, laboratory, and CT parameters of acute patients with acute pulmonary embolism from admission. The outcomes of interest were defined as the occurrence of adverse outcomes within 30 days after admission into hospital.
Eligible patients were randomized in some ratio into derivation and validation cohorts. The derivation cohort was used to develop and evaluate a multivariable logistic regression model for predicting the outcomes of interest. The discriminatory power was evaluated by comparing the nomogram to the established risk stratification systems. The consistency of the nomogram was evaluated using the validation cohort.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: YIZHUO GAO
- Phone Number: +86-18940257523
- Email: gaoyizhuo.sy@hotmail.com
Study Locations
-
-
Liaoning
-
Shenyang, Liaoning, China
- Recruiting
- Shenjing Hospital of CHINA MEDICAL UNIVERSITY
-
Contact:
- YIZHUO GAO
- Phone Number: +86-18940257523
- Email: gaoyizhuo.sy@hotmail.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- age of ≥ 18 years and a PE diagnosis based on CT pulmonary angiography
Exclusion Criteria:
- pregnancy
- reception of reperfusion treatment before admission
- missing data regarding CT parameters, echocardiography, cardiac troponin I (c-Tn I), and N-terminal-pro brain natriuretic peptide (NT-pro BNP) levels.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
---|
Acute pulmonary embolism
an age of ≥ 18 years and a PE diagnosis based on CT pulmonary angiography
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adverse outcomes
Time Frame: 30 days
|
The outcomes of interest were defined as the occurrence of adverse outcomes within 30 days after admission.
Adverse outcomes were defined as PE-related deaths, the need for mechanical ventilation, the need for cardiopulmonary resuscitation, and the need for life-saving vasopressor and reperfusion treatment.
|
30 days
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- AOAPECT
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pulmonary Embolism and Thrombosis
-
Hospital San Carlos, MadridAsociación de Cardiología Intervencionista de la Sociedad Española de CardiologíaRecruitingPulmonary Embolism | Pulmonary Embolism and Thrombosis | Pulmonary Thromboembolisms | Pulmonary Embolism Acute | Pulmonary Embolism Acute MassiveSpain
-
University of California, Los AngelesEnrolling by invitationPulmonary Disease | Pulmonary Embolism | Pulmonary Embolus/Emboli | Pulmonary Embolism and Thrombosis | Pulmonary Embolism Subacute Massive | Pulmonary Embolism Acute MassiveUnited States
-
Brigham and Women's HospitalCompletedDeep Vein Thrombosis, Pulmonary EmbolusUnited States
-
Rennes University HospitalSFMV (French Society of Vascular Medicine)UnknownVenous Thrombosis or Pulmonary EmbolismFrance
-
Pirogov Russian National Research Medical UniversityCompletedDeep Vein Thrombosis, Pulmonary EmbolusRussian Federation
-
Boston Scientific CorporationBTG International Inc.CompletedPulmonary Embolism and ThrombosisUnited States, United Kingdom, Switzerland, Austria, France, Germany, Netherlands, Turkey
-
British Thoracic SocietyCompletedDeep Vein Thrombosis | Pulmonary Embolism | Deep Vein Thrombosis With Pulmonary EmbolismUnited Kingdom
-
Hamilton Health Sciences CorporationCanadian Institutes of Health Research (CIHR)TerminatedDeep Venous Thrombosis | Suspected Pulmonary EmbolismCanada
-
Diagnostica Stago R&DHopital Lariboisière; Hôpital Louis MourierCompletedDeep Vein Thrombosis (DVT) | Pulmonary Embolism (PE)France
-
Washington University School of MedicineMedical Compression SystemsWithdrawnPE - Pulmonary Thromboembolism | DVT - Deep Vein Thrombosis